The Proposed Study Aims to Investigate the Impact of Adjunctive Vitamin D Gel Application on Gingival Crevicular Fluid Levels of Alkaline Phosphatase and Interleukin-8 in Periodontitis Patients Undergoing Phase 1 Periodontal Therapy. By Elucidating the Molecular Mechanisms Underlying the Therapeutic

NCT ID: NCT06669026

Last Updated: 2024-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-01

Study Completion Date

2024-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed study aims to investigate the impact of adjunctive vitamin D gel application on gingival crevicular fluid levels of alkaline phosphatase and interleukin-8 in periodontitis patients undergoing phase 1 periodontal therapy. By elucidating the molecular mechanisms underlying the therapeutic effects of vitamin D, this research seeks to contribute to the development of more effective treatment strategies for periodontitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Pocket

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Group 1: vitamin D3-loaded Poly lactic-co-glycolic acid (PLGA) nanoparticles gel as an adjunct to mechanical debridement.

* Group 2: vitamin D3 gel (regular non-nanoparticle form) as an adjunct to mechanical debridement.
* Group 3: placebo gel as an adjunct to mechanical debridement.
* Group 4: only mechanical debridement.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vitamin D3-loaded Poly lactic-co-glycolic acid nanoparticles gel adjunct to mechanical debridement

vitamin D3-loaded Poly lactic-co-glycolic acid nanoparticles gel adjunct to mechanical debridement, and Interleukin 8/alkaline phosphatase Elisa analysis Frequency: once a week for 8 consecutive weeks Dosage, up to periodontal pocket fil

Group Type EXPERIMENTAL

vitamin D loaded Poly lactic-co-glycolic acid nanoparticles gel

Intervention Type DIETARY_SUPPLEMENT

Scaling and root debridement then inject gel in the pocket

only mechanical debridement

Intervention Type PROCEDURE

Scaling and root debridement

vitamin D3 gel (regular non-nanoparticle form) as an adjunct to mechanical debridement.

vitamin D3 gel (regular non-nanoparticle form) as an adjunct to mechanical debridement, and Interleukin 8/alkaline phosphatase Elisa analysis Frequency: once a week for 8 consecutive weeks Dosage, up to periodontal pocket fil

Group Type ACTIVE_COMPARATOR

vitamin D3 gel (regular non-nanoparticle form)

Intervention Type DIETARY_SUPPLEMENT

Scaling and root debridement then inject gel in the pocket

only mechanical debridement

Intervention Type PROCEDURE

Scaling and root debridement

Poly lactic-co-glycolic acid nanoparticles placebo gel adjunct to mechanical debridement.

Poly lactic-co-glycolic acid nanoparticles placebo gel adjunct to mechanical debridement, and Interleukin 8/alkaline phosphatase Elisa analysis Frequency: once a week for 8 consecutive weeks Dosage, up to periodontal pocket fil

Group Type PLACEBO_COMPARATOR

Poly lactic-co-glycolic acid nanoparticles placebo gel

Intervention Type OTHER

Scaling and root debridement then inject gel in the pocket

only mechanical debridement

Intervention Type PROCEDURE

Scaling and root debridement

only mechanical debridement only

only mechanical debridement only.

Group Type SHAM_COMPARATOR

only mechanical debridement

Intervention Type PROCEDURE

Scaling and root debridement

Healthy patients

healthy patients, only added for Interleukin 8 and alkaline phosphatase Elisa analysis

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vitamin D loaded Poly lactic-co-glycolic acid nanoparticles gel

Scaling and root debridement then inject gel in the pocket

Intervention Type DIETARY_SUPPLEMENT

vitamin D3 gel (regular non-nanoparticle form)

Scaling and root debridement then inject gel in the pocket

Intervention Type DIETARY_SUPPLEMENT

Poly lactic-co-glycolic acid nanoparticles placebo gel

Scaling and root debridement then inject gel in the pocket

Intervention Type OTHER

only mechanical debridement

Scaling and root debridement

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with attachment loss 3-4 mm
* periodontal pocket ≤ 5 mm

Exclusion Criteria

* \- Patients with sensitivity to the medication used in the study.
* Patients with a history of antibiotic use or anti-inflammatory drugs during the previous 3 months prior to the study.
* Patients with systemic diseases.
* Pregnant and lactating females.
* Smokers and tobacco chewers.
* Patients not compliant with oral hygiene procedures.
Minimum Eligible Age

25 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mansoura University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alaaeldin Ahmed Taha

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A0103023OM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.